Histotripsy shows promising safety for treating liver tumors

A real-world safety analysis of histotripsy in 230 liver tumor patients revealed a low complication rate of 5.2%, with the majority classified as minor. Complications greater than grade II were rare, occurring in just 1.3% of cases. This novel non-invasive ultrasound technology, approved by the FDA, demonstrates a favorable safety profile in comparison to existing liver-directed therapies. These findings mark a significant step forward in evaluating this approach for liver tumor treatment.